Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: An Observational Study

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Opstad, Trine B ^a,b   Pettersen, Alf T ^a,b   Arnesen, Harald ^a,b,c   Seljeflot, Ingebjørg ^a,b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Diabetes type 2; Hypertension; IL 18 mrna; Metabolic syndrome; Single nucleotide polymorphisms

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN-18 BINDING PROTEIN; MESSENGER RNA; SIGNAL PEPTIDE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; LEUKOCYTE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETICS; MALE; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 82655180649     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-110     Document Type: Article

References (39)

1. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003, 73(2):213-224. 10.1189/jlb.0602313, 12554798.
2. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88-91. 10.1038/378088a0, 7477296.
3. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997, 275:206-209. 10.1126/science.275.5297.206, 8999548.
4. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10(1):127-136. 10.1016/S1074-7613(00)80013-8, 10023777.
5. Kato Z, Jee J, Shikano H, Mishima M, Ohki I, Ohnishi H, et al. The structure and binding mode of interleukin-18. Nat Struct Biol 2003, 10(11):966-971. 10.1038/nsb993, 14528293.
6. Nold M, Goede A, Eberhardt W, Pfeilschifter J, Muhl H. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol 2003, 367:68-75. 10.1007/s00210-002-0648-5, 12616343.
7. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002, 195(2):245-257. 10.1084/jem.20011022, 2193607, 11805151.
8. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104:1598-1603. 10.1161/hc3901.096721, 11581135.
9. Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia 2009, 52:2101-2108. 10.1007/s00125-009-1455-z, 19669125.
10. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Genth-Zotz S, Post F, et al. Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2008, 15:278-284. 10.1097/HJR.0b013e3282f37a6e, 18525381.
11. Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care 2009, 32(3):486-492. 10.2337/dc08-1710, 2646034, 19092166.
12. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009, 6(3):192-199. 10.1038/ncpcardio1453, 19234499.
13. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003, 108:2453-2459. 10.1161/01.CIR.0000099509.76044.A2, 14581397.
14. Thompson SR, Humphries SE. Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun 2007, 8(2):91-99. 10.1038/sj.gene.6364366, 17215860.
15. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005, 112:643-650. 10.1161/CIRCULATIONAHA.104.519702, 16043644.
16. Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, et al. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: the Helsinki Sudden Death Study. Atherosclerosis 2008, 196:643-649. 10.1016/j.atherosclerosis.2007.07.018, 17765248.
17. Barbaux S, Poirier O, Godefroy T, Kleinert H, Blankenberg S, Cambien F, et al. Differential haplotypic expression of the interleukin-18 gene. Eur J Hum Genet 2007,
18. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001, 112:146-152. 10.1016/S0165-5728(00)00407-0, 11108943.
19. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38:353-356. 10.1080/14017430410024324, 15804802.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 2005, 4(4):198-203. 10.1097/00132577-200512000-00018, 18340209.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
22. Puren AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 1999, 96:2256-2261. 10.1073/pnas.96.5.2256, 26770, 10051628.
23. Liang XH, Cheung W, Heng CK, Wang DY. Reduced transcriptional activity in individuals with IL-18 gene variants detected from functional but not association study. Biochem Biophys Res Commun 2005, 338:736-741. 10.1016/j.bbrc.2005.10.012, 16243298.
24. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, et al. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun 2006, 342:1413-1416. 10.1016/j.bbrc.2006.02.096, 16516851.
25. Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, Woodward M, et al. Interleukin 18 and coronary heart disease: Prospective study and systematic review. Atherosclerosis 2011,
26. Aoyama M, Kotani J, Usami M. Gender difference in granulocyte dynamics and apoptosis and the role of IL-18 during endotoxin-induced systemic inflammation. Shock 2009, 32(4):401-409. 10.1097/SHK.0b013e31819c358a, 19174744.
27. Esposito K, Nappo F, Giugliano F, Di PC, Ciotola M, Barbieri M, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care 2003, 26(5):1647. 10.2337/diacare.26.5.1647, 12716849.
28. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003, 26(9):2622-2627. 10.2337/diacare.26.9.2622, 12941729.
29. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005, 25(6):1268-1273. 10.1161/01.ATV.0000163843.70369.12, 15790931.
30. Troseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 2010, 9:11. 10.1186/1475-2840-9-11, 2858122, 20331890.
31. Weiss TW, Arnesen H, Troseid M, Kaun C, Hjerkinn EM, Huber K, et al. Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose. Wien Klin Wochenschr 2011,
32. Presta I, Andreozzi F, Succurro E, Marini MA, Laratta E, Lauro R, et al. IL-18 gene polymorphism and metabolic syndrome. Nutr Metab Cardiovasc Dis 2009, 19:e5-e6. 10.1016/j.numecd.2008.10.002, 19176284.
33. Troseid M, Seljeflot I, Weiss TW, Klemsdal TO, Hjerkinn EM, Arnesen H. Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome. Atherosclerosis 2010, 209(2):337-339. 10.1016/j.atherosclerosis.2009.09.028, 19836750.
34. Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res 2005, 54(10):395-411. 10.1007/s00011-005-1377-2, 16283107.
35. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503. 10.1172/JCI117619, 330083, 7989608.
36. Chandrasekar B, Marelli-Berg FM, Tone M, Bysani S, Prabhu SD, Murray DR. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 2004, 319(2):304-311. 10.1016/j.bbrc.2004.04.185, 15178407.
37. Muhl H, Kampfer H, Bosmann M, Frank S, Radeke H, Pfeilschifter J. Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun 2000, 267(3):960-963. 10.1006/bbrc.1999.2064, 10673399.
38. Thompson SR, Novick D, Stock CJ, Sanders J, Brull D, Cooper J, et al. Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol 2007, 27(12):2743-2749. 10.1161/ATVBAHA.107.149245, 17951325.
39. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001, 14(6):334-342. 10.1006/cyto.2001.0914, 11497494.